Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survival after neoadjuvant vs adjuvant chemotherapy in resectable pancreatic cancer with risk factors
2021-000317-17Phase 3Active
- Sponsor
- INIBICA
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan, fluorouracil, oxaliplatin and folinic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by INIBICA. Primary endpoint: Overall survival. Started Jun 2021; status: active.
02
Drugs
irinotecanfluorouraciloxaliplatinfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2021-000317-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000317-17.